EASTERN COOPERATIVE ONCOLOGY GROUP

比勒陀利亚大学一直是东部的主要成员 自1972年以来一直在肿瘤协作组（ECOG）工作。 本申请要求 继续参与西非经共体的必要支持， 比勒陀利亚大学。 作为ECOG的成员，该机构是 试图改善癌症患者的质量和持续时间， 通过开发和科学评估最有效的 所有类型和阶段的癌症的治疗方案。 具体目标 包括： 1.在所有研究中维持完全可评价患者的高入组率 ECOG治疗和非治疗方案。 2.维护和完善有效的数据管理程序。 在 1991年11月，ECOG统计中心卓越数据奖 管理奖授予比勒陀利亚大学， 在提交给联合国系统的数据质量评价中得分最高的国家 参与机构的ECOG统计中心。 3.继续为创新治疗的发展做出贡献 协议和继续领导ECOG的科学计划。 比勒陀利亚的研究人员主持或曾主持过许多ECOG研究， 各种疾病领域。 这些包括恶性黑素瘤（EST 3690）， 乳腺癌（EST 2177，EST 1179，EST 2181，EST 4181），原发性肝癌 癌症（EST 2273，EST 1280，EST 2282），间皮瘤（EST P-A 380，EST P-A 783，EST 1786）和食管癌（EST 2287）。 的调查人员 比勒陀利亚是许多ECOG研究的共同主席。 校长 研究者担任ECOG乳腺癌委员会主席 1981-1982年，比勒陀利亚继续是临床的主要资源， 乳腺癌的临床试验 4.发表ECOG研究结果。 G·法尔科森是 1983 - 1990年ECOG乳腺癌数据库审查委员会。 以来 最后一次申请公共卫生服务补助金的比勒陀利亚医生是作者 在ECOG研究的71篇出版物中， 19篇论文的作者。 5.继续提供ECOG收集的科学信息， 国家和国际会议。 6.为ECOG和NCI肝细胞癌项目做出贡献， 食道癌和间皮瘤，比勒陀利亚有独特的资源， 这是迄今为止所做工作的证明。

The University of Pretoria has been a leading member of the Eastern Cooperative Oncology Group (ECOG) since 1972. This application requests the support necessary for continued participation in ECOG by the University of Pretoria. As a member of ECOG, this institution is attempting to improve both the quality and duration of cancer patients lives by developing and scientifically evaluating the most effective treatment programs for all types and stages of cancer. The specific aims of this proposal include: 1. To maintain a high accrual rate of fully evaluable patients on all ECOG therapeutic and non-therapeutic protocols. 2. To maintain and refine an effective data management program. In November 1991, the ECOG Statistical Center Award for Excellence in Data Management was awarded to the University of Pretoria for achieving the highest score in the evaluation of the quality of data submitted to the ECOG Statistical Center by participating institutions. 3. Continued contribution to the development of innovative treatment protocols and continued leadership in the scientific programs of ECOG. Investigators in Pretoria chair or have chaired numerous ECOG studies in various disease areas. These include malignant melanoma (EST 3690), breast cancer (EST 2177, EST 1179, EST 2181, EST 4181), primary liver cancer (EST 2273, EST 1280, EST 2282), mesothelioma (EST P-A 380, EST P-A 783, EST 1786) and esophagus cancer (EST 2287). Investigators from Pretoria are co-chairmen on numerous ECOG studies. The principal investigator served as Chairman of the Breast Cancer Committee of ECOG 1981-1982 and Pretoria continues to be a major resource for clinical trials in Breast Cancer. 4. To publish results of ECOG studies. G Falkson was chairman of the Breast Cancer Data Base Review Committee of ECOG from 1983 - 1990. Since the last application for a PHS Grant Pretoria doctors have been authors of 71 publications resulting from ECOG studies of which they were first authors in 19 publications. 5. To continue to present the scientific information gathered by ECOG at national and international meetings. 6. To contribute to ECOG and NCI programs on hepatocellular carcinoma, esophagus cancer, and mesothelioma where Pretoria has unique resources as evidence by the work done so far.